Procedural Rules in Arbitration

Arbitral Tribunal – The decision‑making body in arbitration, usually composed of one or three arbitrators selected by the parties or appointed by an institution. In health‑law disputes, the tribunal may include a medical expert to assist with technical issues such as clinical standards or pharmaceutical regulations. The tribunal’s authority derives from the parties’ agreement and the applicable procedural rules.

Arbitration Agreement – The contractual clause or separate agreement that obligates the parties to submit their disputes to arbitration. It must be in writing and clearly express the intent to arbitrate. In the health sector, arbitration agreements are commonly embedded in hospital‑provider contracts, pharmaceutical supply agreements, and health‑insurance policies. A well‑drafted agreement specifies the scope of disputes, the chosen institution or ad‑hoc method, and the seat of arbitration.

Seat of Arbitration – The legal place where the arbitration is deemed to be seated. It determines the procedural law (lex arbitri) that governs the arbitration’s conduct, including the court’s supervisory powers. For example, a dispute between a U.S. hospital and a German medical device manufacturer might be seated in London, thereby applying English arbitration law and allowing recourse to the English courts for interim measures.

Lex Arbitri – The law of the seat of arbitration that provides the procedural framework for the arbitration. It influences issues such as the appointment of arbitrators, the conduct of hearings, and the enforceability of awards. In health‑law cases, lex arbitri may affect the admissibility of medical records, the confidentiality of patient information, and the availability of expert testimony.

Institutional Rules – The set of procedural rules published by an arbitration institution (e.g., ICC, LCIA, SIAC, AAA). These rules supplement the parties’ agreement and provide a standardized framework for case management, document production, and award issuance. Institutions often have specialized provisions for sensitive sectors such as health, including safeguards for patient privacy and provisions for the appointment of medical experts.

Ad Hoc Arbitration – An arbitration conducted without the assistance of an institution, relying solely on the parties’ agreement and any applicable national arbitration law. While ad hoc proceedings allow greater flexibility, they may lack the procedural support that institutions provide, such as a secretariat to manage timelines and document filings. In health‑law disputes, parties sometimes prefer ad hoc arbitration to maintain tighter control over confidentiality.

Procedural Timetable – The schedule of procedural steps agreed upon by the parties or imposed by the arbitral institution. It includes deadlines for the filing of statements of claim, defenses, evidence, and the hearing. A clear timetable is essential in health‑law cases where timely resolution can affect patient care, regulatory compliance, and insurance reimbursements.

Statement of Claim – The initial pleading filed by the claimant outlining the factual and legal basis of the dispute, the relief sought, and the evidentiary material. In a medical malpractice arbitration, the statement of claim would detail the alleged breach of the standard of care, the injuries sustained, and the monetary damages claimed.

Statement of Defense – The respondent’s written answer to the claim, addressing each allegation and presenting any counter‑claims or affirmative defenses. In health‑law arbitration, the defense may invoke statutory immunities, compliance with regulatory standards, or lack of causation.

Written Submissions – All documents exchanged between the parties, including pleadings, evidentiary lists, and legal arguments, submitted in writing before the hearing. Institutions often require that written submissions be concise and focused on the key issues to avoid unnecessarily prolonging the proceedings.

Document Production – The process by which parties request and exchange relevant documents. In health‑law arbitrations, document production may involve medical records, clinical trial data, regulatory filings, and insurance policies. Rules governing document production typically balance the need for full disclosure against confidentiality and data‑privacy concerns.

Confidentiality – The duty to keep arbitration proceedings and related documents private, unless the parties agree otherwise or a court orders disclosure. Health‑law arbitrations frequently invoke confidentiality to protect patient information, trade secrets, and proprietary clinical data. However, confidentiality may clash with public‑policy considerations, such as the need to disclose safety information about a medical device.

Evidence – The material presented to establish the facts of the case. In arbitration, evidence can be documentary, testimonial, or expert. The admissibility and weight of evidence are determined by the procedural rules and the tribunal’s discretion. Health‑law arbitrations often rely heavily on expert testimony to interpret clinical standards and regulatory compliance.

Expert Witness – An individual with specialized knowledge who provides opinion evidence on technical matters. In health‑law disputes, experts may be physicians, pharmacists, epidemiologists, or health‑policy analysts. Parties typically disclose expert reports well before the hearing to allow the tribunal and the opposing side to assess the credibility and relevance of the expert’s conclusions.

Witness Statement – A written account of a fact‑witness’s testimony, usually submitted in advance of the hearing. Witness statements streamline the hearing by reducing the need for live testimony, but parties may still cross‑examine witnesses in person if credibility is contested.

Hearing – The oral phase of arbitration where parties present arguments, examine witnesses, and respond to the tribunal’s questions. Hearings can be conducted in person, via video conference, or through a hybrid format. In health‑law cases, hearings may involve live demonstrations of medical equipment or the presentation of complex statistical data.

Procedural Fairness – The principle that the arbitration process must be conducted in a manner that respects the parties’ rights to be heard, to present evidence, and to obtain a reasoned decision. Procedural fairness is a cornerstone of enforceability; awards rendered in procedurally unfair arbitrations are vulnerable to challenge in national courts.

Due Process – A broader concept encompassing procedural fairness, but also including the right to an impartial tribunal, the right to a fair and public hearing (subject to confidentiality), and the right to a reasoned award. While due process is most often associated with judicial proceedings, many jurisdictions apply it to arbitration, especially where public health and safety are at stake.

Impartiality – The requirement that arbitrators must be free from bias or conflicts of interest. In health‑law arbitrations, potential conflicts may arise if an arbitrator has previously served as a consultant for a pharmaceutical company or holds shares in a medical‑device manufacturer. Disclosure obligations and challenge procedures help safeguard impartiality.

Challenge of Arbitrator – The procedural mechanism by which a party seeks to remove an arbitrator for cause (e.g., bias, lack of independence) or for lack of qualifications. Challenges must be raised promptly and supported by specific facts. In health‑law disputes, a challenge may be based on an arbitrator’s prior involvement in a related regulatory proceeding.

Appointment of Arbitrators – The process by which arbitrators are selected. Parties may each appoint one arbitrator, and those two may select a third, or an institution may appoint arbitrators on the parties’ behalf. The appointment process should reflect the need for technical expertise in health‑law matters, ensuring that at least one arbitrator possesses a background in medicine or health policy.

Joinder – The addition of a third party to the arbitration who has an interest in the dispute. Joinder may be appropriate when a medical device manufacturer is sued by a hospital and a third‑party distributor claims it is also liable. Rules governing joinder vary, but typically require the consent of the existing parties and a demonstration that the joinder will not unduly delay the proceedings.

Consolidation – The merging of two or more related arbitrations into a single proceeding. Consolidation is useful when multiple health‑law disputes arise from the same clinical trial or product launch. Institutions may order consolidation to avoid inconsistent awards and to achieve economies of scale.

Stay of Arbitration – A court order that temporarily suspends the arbitration proceedings. Stays may be sought when parallel litigation is pending, when a party alleges that the arbitration would be premature, or when a regulatory authority initiates an investigation that could affect the outcome. In health‑law contexts, a stay may be requested to allow a regulatory review of a medical device’s safety to conclude before the arbitration proceeds.

Award – The final decision rendered by the arbitral tribunal, resolving the dispute and specifying any monetary or non‑monetary relief. Awards can be a “final and binding” award, a “partial award” addressing only certain issues, or an “interim award” granting temporary relief. In health‑law arbitrations, awards may order the payment of damages, the issuance of injunctions to cease the distribution of a defective product, or the implementation of corrective measures.

Reasoned Award – An award that includes the tribunal’s findings of fact and the legal reasoning supporting its decision. A reasoned award enhances enforceability and reduces the likelihood of successful challenges. In health‑law cases, a reasoned award should explain how the tribunal applied medical standards, regulatory frameworks, and contractual provisions to the facts.

Costs – The expenses incurred in the arbitration, including arbitrators’ fees, institutional fees, legal representation, expert fees, and administrative costs. Cost awards may be allocated based on the parties’ conduct, the outcome of the dispute, or the principle of “costs follow the event.” Health‑law arbitrations often involve high expert fees, making cost allocation a critical consideration.

Cost‑Shifting – The practice of awarding costs to the losing party, or in some cases, allocating costs proportionally based on the merit of each party’s position. Cost‑shifting can incentivize parties to settle early and to avoid frivolous claims, which is particularly important in the health sector where litigation costs can be substantial.

Enforcement – The process of obtaining compliance with an arbitral award, typically through national courts. The 1958 New York Convention on the Recognition and Enforcement of Foreign Arbitral Awards provides a widely adopted framework for enforcement. In health‑law cases, enforcement may involve seizing assets of a pharmaceutical company or ordering the payment of compensation to patients.

Recognition – The court’s acknowledgment that an arbitral award is valid and enforceable. Recognition is a prerequisite to enforcement. Grounds for refusal of recognition under the New York Convention include lack of proper notice, the award’s violation of public policy, or the tribunal’s lack of jurisdiction. Public‑policy objections are common in health‑law arbitrations when an award appears to contravene mandatory health‑safety regulations.

Public Policy – The fundamental principles and standards of a jurisdiction that may be invoked to refuse enforcement of an award. In health‑law contexts, public policy may protect patients’ rights, ensure compliance with drug‑approval procedures, or uphold mandatory insurance obligations. Courts carefully balance the respect for arbitration autonomy with the need to protect public health.

Appeal – The limited right to challenge an arbitral award in a national court. Most jurisdictions restrict appeals to narrow grounds such as procedural irregularities, excess of authority, or serious errors of law. Health‑law parties may seek appeal if they believe the tribunal misapplied medical standards or ignored mandatory regulatory provisions.

Set‑Aside – A court action that seeks to nullify an arbitral award. Grounds for set‑aside mirror those for refusal of enforcement, including lack of jurisdiction, procedural unfairness, or violation of public policy. In health‑law disputes, a set‑aside may be pursued if the award awards damages that are inconsistent with statutory caps on medical‑malpractice compensation.

Interim Measures – Temporary orders issued by the tribunal (or by a national court) to preserve the status quo, protect evidence, or prevent irreparable harm while the arbitration proceeds. Common interim measures in health‑law arbitrations include injunctions to halt the distribution of a suspect drug, preservation orders for medical records, or orders to maintain ongoing patient care.

Preservation Order – An order directing a party to retain documents or evidence that might be destroyed or altered. In disputes over clinical trial data, preservation orders are crucial to ensure that the tribunal has access to the original data sets for accurate assessment.

Security for Costs – A requirement that a party deposit a sum of money to cover potential costs awarded against it. Courts may order security for costs when a party appears unlikely to satisfy a cost award, such as a financially weak health‑care provider. Security for costs helps protect the prevailing party from non‑payment.

Conflicts of Law – The set of rules that determines which jurisdiction’s substantive law applies to the dispute. In health‑law arbitration, conflicts of law may arise when the parties are from different countries and the dispute involves cross‑border medical services, pharmaceutical distribution, or tele‑medicine. The tribunal must decide which law governs the contract, tort, and regulatory issues.

Governing Law – The substantive law chosen by the parties to govern their contract and the dispute. A clear governing‑law clause reduces uncertainty and guides the tribunal’s analysis of liability, damages, and statutory limitations. In health‑law contracts, parties often select the law of a jurisdiction with well‑developed medical‑liability statutes.

Limitation Period – The time limit within which a claim must be brought. Arbitration rules may provide that the limitation period of the governing law applies, or they may set a procedural time limit. Health‑law claims, such as those for medical negligence, often have strict limitation periods, making timely filing essential.

Confidentiality Agreement – A separate contract that reinforces or expands the confidentiality provisions of the arbitration agreement. It may specify the handling of sensitive patient data, proprietary clinical information, and the scope of permissible disclosures. Violations of a confidentiality agreement can lead to damages and may affect the enforceability of the award.

Procedural Order – An order issued by the tribunal to manage the conduct of the arbitration, such as setting deadlines, ordering the production of documents, or granting a request for a hearing postponement. Procedural orders help maintain efficiency and ensure that the arbitration proceeds in an orderly fashion.

Adjournment – The postponement of a hearing or procedural deadline, usually granted upon a party’s request and the tribunal’s discretion. Adjournments may be necessary in health‑law cases where additional expert evidence is needed or where a party is awaiting the outcome of a regulatory investigation.

Waiver – The voluntary relinquishment of a known right. In arbitration, a party may waive the right to a particular procedural step by failing to raise an objection within the prescribed time. Waivers can be strategic, but in health‑law disputes, parties must be careful not to waive rights that protect patient safety or regulatory compliance.

Objection – A formal protest raised by a party against a procedural action, such as the admission of evidence, the appointment of an arbitrator, or the jurisdiction of the tribunal. Objections must be made promptly and with sufficient basis to be considered by the tribunal.

Jurisdiction – The authority of the arbitral tribunal to hear and decide the dispute. Jurisdiction may be challenged on the basis that the dispute falls outside the scope of the arbitration agreement, that the parties lacked capacity to agree to arbitration, or that the claim is not arbitrable under the applicable law. Health‑law disputes often raise jurisdictional questions concerning the arbitrability of regulatory enforcement actions.

Arbitrability – The determination of whether a particular type of dispute can be resolved by arbitration. Certain health‑law matters, such as criminal prosecutions for fraud or violations of mandatory health‑safety statutes, may be deemed non‑arbitrable. Courts and tribunals must assess whether the subject matter is suitable for private adjudication.

Severability – A clause that ensures that if any provision of the arbitration agreement is found to be invalid or unenforceable, the remainder of the agreement remains in effect. Severability is important in health‑law contracts where specific clauses may conflict with mandatory statutory requirements.

Force Majeure – A contractual provision that excuses performance when unforeseen events beyond the parties’ control occur. In health‑law agreements, force‑majeure clauses may address pandemics, natural disasters, or sudden regulatory bans on a medical product. The clause’s scope can affect the tribunal’s assessment of breach and damages.

Amendment – The process by which the parties modify the arbitration agreement or procedural timetable. Amendments typically require the consent of all parties and, when institutional rules are involved, may need the institution’s approval. In health‑law disputes, amendments may be necessary to accommodate new evidence or regulatory developments.

Termination – The conclusion of the arbitration process, either by the issuance of an award, by settlement, or by the parties’ mutual agreement to discontinue the proceeding. Termination may also occur if the tribunal determines that it lacks jurisdiction and dismisses the case.

Settlement – The resolution of the dispute through agreement between the parties, without a final award. Settlement is common in health‑law arbitrations, where parties may wish to avoid public disclosure of sensitive medical information or to preserve ongoing commercial relationships. Settlement agreements may be incorporated into the award or remain confidential.

Confidential Settlement – A settlement that is not disclosed to the public, often reinforced by a confidentiality clause. In health‑law contexts, confidential settlements protect patient privacy and proprietary clinical data, but they may raise concerns if the settlement conceals systemic safety issues.

Arbitration Clause – A provision within a contract that mandates arbitration as the method of dispute resolution. It typically identifies the scope of disputes covered, the chosen institution or ad‑hoc method, the seat of arbitration, and the governing law. The clarity of an arbitration clause is vital to avoid later jurisdictional disputes.

Arbitration Rules – The procedural framework established by an institution or the parties, governing the conduct of the arbitration. Rules cover matters such as the number of arbitrators, the format of hearings, the handling of evidence, and the issuance of awards. Health‑law institutions may adopt specialized rules to address the handling of clinical data and patient confidentiality.

Procedural Flexibility – The ability of the arbitration process to adapt to the specific needs of the parties and the dispute. Flexibility is one of arbitration’s key attractions, allowing parties to tailor procedures to the technical complexity of health‑law matters, such as using virtual hearings or limiting the number of expert witnesses.

Procedural Rigor – The degree of formality and strictness applied to the arbitration process. While flexibility is valued, procedural rigor ensures that the parties receive a fair and transparent process, especially when high stakes, such as large compensation claims or public‑health implications, are involved.

Standard of Review – The level of scrutiny applied by a court when reviewing an arbitral award. Courts typically apply a “manifest disregard of the law” standard, meaning they will not overturn an award unless the tribunal egregiously ignored applicable law. In health‑law cases, a narrow standard of review underscores the importance of a well‑reasoned award.

Manifest Disregard – A ground for set‑aside when a tribunal knowingly and intentionally ignores binding legal principles. Demonstrating manifest disregard is difficult, requiring proof that the tribunal was aware of the relevant law and deliberately chose to disregard it. Health‑law arbitrations must therefore ensure that tribunals are thoroughly briefed on applicable medical statutes and regulations.

Arbitral Institution – An organization that administers arbitration, providing rules, secretarial support, and sometimes a roster of qualified arbitrators. Institutions such as the International Chamber of Commerce (ICC), the London Court of International Arbitration (LCIA), and the Singapore International Arbitration Centre (SIAC) have dedicated health‑law arbitration panels.

Arbitral Secretarial Services – Administrative assistance offered by an institution, including the management of filings, the scheduling of hearings, and the distribution of documents. Secretarial services are particularly valuable in complex health‑law disputes where the volume of evidence can be overwhelming.

Arbitral Fees – The remuneration paid to arbitrators for their services. Fees are usually calculated based on the amount in dispute, the number of arbitrators, and the time spent on the case. In high‑value health‑law arbitrations, fees can be substantial, making cost‑management an essential part of case strategy.

Institutional Administration Fee – The charge levied by an arbitration institution for the provision of its procedural framework and secretarial services. The fee structure may be tiered, reflecting the complexity and duration of the arbitration. Health‑law parties often negotiate fee caps to control expenses.

Emergency Arbitration – A fast‑track procedure that allows a party to obtain interim relief before the tribunal is fully constituted. Emergency arbitrators can issue orders on matters such as the preservation of evidence or the suspension of a medical device’s distribution. Emergency arbitration is increasingly used in health‑law disputes where immediate action is required to protect patients.

Emergency Arbitrator – An arbitrator appointed on an expedited basis to handle urgent matters. The emergency arbitrator’s authority is limited to interim measures and does not extend to the final award. The appointment of an emergency arbitrator may be stipulated in the institution’s rules or in the parties’ agreement.

Provisional Remedy – An interim measure that provides temporary relief, similar to an injunction, pending the final determination of the dispute. In health‑law arbitrations, provisional remedies may include ordering a pharmaceutical company to recall a drug or requiring a hospital to continue providing emergency services.

Arbitration Clause Drafting – The practice of carefully constructing an arbitration clause to anticipate potential procedural and substantive issues. Effective drafting addresses the scope of disputes, the choice of institution, the seat, the governing law, confidentiality, and the method of appointing arbitrators. In health‑law contracts, drafting must also consider regulatory constraints and patient‑privacy obligations.

Regulatory Immunity – The protection afforded to government agencies from being sued in private arbitration for performing their regulatory duties. While regulatory immunity can limit the arbitrability of certain health‑law disputes, parties may still arbitrate contractual claims arising from regulatory interactions, such as compliance‑related breaches.

Public‑Interest Exception – A principle that allows courts to intervene in arbitration when the dispute raises significant public‑policy concerns. In health‑law contexts, courts may refuse to enforce an award that undermines mandatory safety standards or that jeopardizes public health.

Confidentiality Waiver – A provision that permits limited disclosure of arbitration information, often for regulatory or enforcement purposes. Parties may agree to a confidentiality waiver to allow a health‑authority to review the award’s findings without compromising patient privacy.

Documentary Evidence – Tangible records submitted to support a party’s case. In health‑law arbitrations, documentary evidence may include electronic health records, clinical trial protocols, FDA approval letters, and insurance claim files. The admissibility of documentary evidence is governed by the procedural rules and the tribunal’s discretion.

Electronic Submission – The filing of documents and evidence through an online portal provided by the institution. Electronic submission enhances efficiency, particularly in health‑law disputes where large data sets and imaging files may need to be exchanged securely.

Data‑Privacy Compliance – The obligation to protect personal health information in accordance with laws such as the General Data Protection Regulation (GDPR) or the Health Insurance Portability and Accountability Act (HIPAA). Arbitrators must ensure that the handling of medical records respects data‑privacy requirements, and parties may need to obtain patient consent before disclosure.

Hearing Record – A transcript or recording of the oral proceedings. The hearing record may be used for appellate review or for future reference. In health‑law arbitrations, the record may include expert testimony on clinical standards, making accurate transcription critical.

Award Enforcement Strategy – The plan for obtaining compliance with the award, which may involve filing a petition with a national court, pursuing asset seizure, or negotiating a payment plan. A well‑crafted enforcement strategy is essential when the losing party is a multinational corporation with assets in multiple jurisdictions.

Cross‑Border Enforcement – The process of enforcing an award in a jurisdiction different from where the arbitration took place. The New York Convention facilitates cross‑border enforcement, but local public‑policy considerations, especially in health‑law matters, can affect success. Parties should anticipate enforcement challenges when selecting the seat and governing law.

Arbitration Cost Budget – The financial plan outlining anticipated expenses for the arbitration, including arbitrators’ fees, expert fees, travel, and administrative costs. Health‑law arbitrations often require sizable budgets due to expert involvement and extensive document production.

Cost Management – The practice of controlling arbitration expenses through measures such as limiting the number of experts, using document‑production protocols, and agreeing on a fixed‑fee arrangement for the tribunal. Effective cost management helps preserve the economic benefits of arbitration.

Case Management Conference – A meeting, often conducted virtually, where the tribunal and the parties discuss procedural matters, set timelines, and address any obstacles. The conference is an opportunity to streamline the process, especially when dealing with voluminous health‑law evidence.

Procedural Objection – An objection raised concerning the manner in which the arbitration is being conducted, such as a claim that a deadline was missed or that a document request is overly broad. The tribunal must address procedural objections promptly to maintain fairness.

Jurisdictional Challenge – A claim that the tribunal lacks authority to hear the dispute. In health‑law arbitrations, jurisdictional challenges may arise when a party argues that the dispute involves a statutory violation that cannot be arbitrated. The tribunal’s decision on jurisdiction can be appealed in limited circumstances.

Arbitration Confidentiality Order – An order issued by the tribunal to preserve confidentiality of certain materials, such as patient records or proprietary clinical data. The order may specify the handling, storage, and limited access to confidential documents.

Protective Measures – Steps taken to safeguard sensitive information during the arbitration, such as redaction of identifying details, secure electronic portals, and non‑disclosure agreements for counsel and experts. Protective measures are especially crucial in health‑law disputes to comply with privacy laws.

Arbitration Clause Interpretation – The process of construing the language of the arbitration clause to determine its scope and applicability. Courts may be called upon to interpret ambiguous clauses, and the prevailing approach is to give effect to the parties’ intent. In health‑law contracts, clarity in the clause can prevent disputes over whether a regulatory action is arbitrable.

Arbitration Settlement Agreement – A contract that records the terms of a settlement reached during arbitration. The agreement may be incorporated into the award, making it enforceable under the same mechanisms as a judgment. Parties may choose to keep the settlement confidential, especially when it involves medical‑technology licensing terms.

Medical‑Expert Witness Report – A written document prepared by a qualified medical professional, outlining their opinion on clinical issues central to the dispute. The report must be detailed, citing relevant standards of care, guidelines, and literature. Early exchange of expert reports facilitates efficient case management.

Statutory Caps – Legislative limits on the amount of damages that can be awarded for certain types of claims, such as medical‑malpractice compensation. Arbitrators must apply statutory caps when calculating damages, and parties should be aware of these limits when framing their claims and defenses.

Damages Calculation – The method used to quantify monetary compensation, which may include economic losses (e.g., medical expenses, lost earnings) and non‑economic losses (e.g., pain and suffering). In health‑law arbitrations, damages calculation often requires detailed financial analysis and expert testimony.

Punitive Damages – Additional damages awarded to punish egregious conduct and deter future wrongdoing. Many jurisdictions restrict punitive damages in health‑law cases, especially where statutory schemes provide specific remedies. Arbitrators must consider the applicable law when deciding whether punitive damages are available.

Injunction – An equitable remedy that orders a party to do or refrain from doing a specific act. In health‑law arbitrations, injunctions may be used to stop the marketing of a defective medical device or to compel the provision of emergency medical services.

Specific Performance – An order requiring a party to fulfill a contractual obligation, rather than paying monetary damages. Specific performance is rare in health‑law arbitrations but may be appropriate where a contract requires the delivery of essential medical equipment.

Confidentiality of Awards – The principle that the content of the award may be kept private, unless the parties agree to disclose it or a court orders publication. Confidentiality of awards is valuable in health‑law disputes to protect patient identities and proprietary information.

Award Publication – The act of making the award publicly available. Publication may be required by law in certain jurisdictions or may be requested by regulators to inform the public about safety concerns. Parties must balance transparency with privacy considerations.

Arbitration Appeal Clause – A provision that allows parties to appeal the award to a higher tribunal or court. Such clauses are uncommon, as arbitration is intended to be final, but they may be included in complex health‑law contracts where parties desire an additional layer of review.

Arbitration Review Committee – A body established by some institutions to review procedural matters or to address challenges to arbitrators. The committee can provide an additional safeguard against bias or procedural irregularities, enhancing confidence in health‑law arbitrations.

Arbitration Transparency Initiative – An industry effort to increase the openness of arbitration proceedings while preserving confidentiality where necessary. In health‑law, transparency initiatives may focus on sharing anonymized data about medical‑device disputes to improve industry standards.

Arbitrator’s Conflict‑of‑Interest Disclosure – The requirement that arbitrators disclose any relationships or interests that could affect their impartiality. Disclosure forms typically ask about prior consulting work, shareholdings, or personal connections to the parties. In health‑law arbitrations, even indirect connections to a pharmaceutical company may be relevant.

Arbitration Confidentiality Waiver Clause – A clause that permits limited disclosure of arbitration materials to regulators, auditors, or other authorized entities. The clause must define the scope of the waiver and any protective measures required.

Arbitration Confidentiality Order – A tribunal order that mandates the protection of confidential information, specifying handling procedures, access restrictions, and penalties for breach. The order may be essential when the arbitration involves sensitive patient data.

Arbitration Confidentiality Protocol – A set of procedures adopted by the parties and the tribunal to safeguard confidential information, including secure document exchange platforms, encrypted video conferencing, and non‑disclosure agreements for all participants.

Arbitration Hearing Protocol – The procedural rules governing the conduct of the hearing, such as time limits for oral arguments, the order of witness examination, and the use of visual aids. A clear hearing protocol helps manage the complexity of health‑law evidence.

Arbitration Schedule – A detailed timetable that outlines the dates for the exchange of pleadings, the production of documents, the submission of expert reports, and the hearing. In health‑law arbitrations, the schedule must accommodate the time needed for expert analysis of clinical data.

Arbitration Case Management Plan – A strategic document prepared by the tribunal and the parties to coordinate the procedural steps, allocate resources, and address potential bottlenecks. The plan may include provisions for virtual hearings, parallel proceedings, and interim measures.

Arbitration Confidentiality Guidelines – Best‑practice recommendations issued by institutions or professional bodies on how to handle confidential information. Guidelines may address redaction techniques, data‑security standards, and the preservation of privilege.

Arbitration Cost Allocation – The method by which the costs of the arbitration are apportioned between the parties. Common approaches include “costs follow the event,” “equal split,” or “proportional to success.” In health‑law arbitrations, cost allocation may reflect the relative sophistication of the parties and the complexity of the expert evidence.

Arbitration Cost Advance – A pre‑payment of anticipated costs, often required by the institution to ensure that fees can be covered. The advance may be adjusted as the arbitration progresses, and any surplus is returned at the conclusion.

Arbitration Cost Reserve – An amount set aside to cover unforeseen expenses, such as additional expert testimony or extended hearings. The reserve provides flexibility to address unexpected developments in health‑law disputes.

Arbitration Cost Dispute – A disagreement between the parties regarding the amount or allocation of costs. Cost disputes may be resolved by the tribunal through a cost award or may be referred to a court for determination.

Arbitration Cost Recovery – The process by which a party seeks to recover costs incurred in the arbitration, typically through a cost award. Cost recovery may be limited by statutory caps or by the institution’s rules.

Arbitration Cost Disclosure – The requirement that parties disclose the anticipated costs of the arbitration to each other, fostering transparency and enabling informed decision‑making. Cost disclosure is especially relevant when one party is a smaller health‑care provider facing a larger corporate opponent.

Arbitration Cost Management Agreement – An agreement between the parties that sets out the terms for managing and sharing costs, including caps, payment schedules, and mechanisms for adjusting costs as the case evolves.

Arbitration Fee Schedule – The published list of fees charged by an institution for its services, including administrative fees, arbitrator fees, and optional services such as expedited procedures. Parties should review the fee schedule when budgeting for a health‑law arbitration.

Arbitration Confidentiality Clause – A clause within the arbitration agreement that obligates the parties to keep the proceedings, documents, and award confidential. The clause may specify exceptions, such as disclosures required by law or regulatory authorities.

Arbitration Confidentiality Exception – A provision that allows certain disclosures despite the confidentiality clause, typically for compliance with legal obligations, court orders, or public‑policy reasons. In health‑law cases, an exception may be necessary to report adverse events to a health regulator.

Arbitration Confidentiality Obligation – The duty imposed on parties, counsel, experts, and arbitrators to maintain the confidentiality of arbitration materials. Breach of the obligation can result in damages, sanctions, or adverse cost awards.

Arbitration Confidentiality Enforcement – The mechanisms by which a breach of confidentiality is addressed, which may include injunctive relief, monetary penalties, or disciplinary measures against counsel. Enforcement is critical to preserve the integrity of health‑law arbitrations.

Arbitration Confidentiality Breach – An unauthorized disclosure of confidential information. In health‑law arbitrations, a breach could expose patient data, leading to legal liability under data‑privacy statutes.

Arbitration Confidentiality Remedy – The relief granted to a party harmed by a confidentiality breach, which may include damages, an order to cease further disclosure, and an award of costs. Remedies aim to deter future breaches and compensate for any harm caused.

Arbitration Confidentiality Standard – The level of protection required for confidential information, often aligned with industry standards for data security. In health‑law arbitrations, the standard may be comparable to the security measures required for electronic health records.

Arbitration Confidentiality Assurance – A guarantee provided by the parties or the institution that appropriate safeguards are in place to protect confidential information.